Skip to main content

Advertisement

Table 4 Cost per QALY from societal perspective

From: Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis

GBS carrier % of meningitis cases with long-term sequelae
Prevalence 22.5% 35% 47.5% 60%
0.2000 222,459 152,325 86,209 24,031
0.2525* 117,993 63,072 10,641 cs
0.3000 71,705 23,138 cs cs
  1. * baseline rate.
  2. cs denotes cost-saving.